ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GKL-006RTU

A development code. Also written as “GKL-006RTU injection”.

Its studies are mostly in Acute Lung Injury, led by Beijing Gene Key Life Technology.

Furthest: phase 2, since Jun 29, 20261 company-led study, 1 open or runningNext primary completion: Dec 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Gene Key Life Technology11 open or runningphase 2since Jun 29, 2026Jun 29, 2026Dec 30, 2028phase 2 · NCT07706855

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 29, 2026First study: phase 2 study in Acute Lung InjuryFirst studyNCT07706855 · 52 planned
  2. Sep 30, 2026Primary completion moved from 2027-07-30 to 2028-12-30Date moved laterphase 2 · +17 months · NCT07706855

Ahead

  1. Dec 30, 2028Primary completion: phase 2 study in Acute Lung InjuryNCT07706855

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07706855Acute Lung Injury2Not yet recruitingDec 30, 202852

How it is read

Names in the registry

  • “GKL-006RTU injection”, 1 entry

Codes read as this program: GKL006RTU.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.